The neurotoxicity and safety of treatment with cefepime in patients with renal failure

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 966-970

  Sonck, J ^a   Laureys, G ^a   Verbeelen, D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Cefepime; Kidney disease; Neurotoxicity; Renal failure

Indexed keywords

CEFEPIME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; AGITATION; APHASIA; ARTICLE; CAUSE OF DEATH; CHOREOATHETOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMA; CONFUSION; CONVULSION; DELTA RHYTHM; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY FAILURE; LATENT PERIOD; MALE; MYOCLONUS; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; SYMPTOM; BACTERIAL INFECTION; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; MIDDLE AGED; PATHOPHYSIOLOGY; TOXICITY AND INTOXICATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 42449092512     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm713     Document Type: Article

References (26)

1. Rybak M. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Am J Med. 1996; 100: 39S-44S
2. Barbhaiya RH, Knupp CA, Forgue ST et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990; 48: 268-76
3. Johnson H, Walter A. Intraventricular penicillin: a note of warning. JAMA. 1945; 127: 217-219
4. Sanford JP, Gilbert DN, Moellering RC et al. The Sanford Guide to Antimicrobial Therapy 2005-2006, . of the Belgian/Luxembourg version. Antimicrobila Therapy Inc. PO Box 70, Hyde Park, Vermont 05655, US: 2006.
5. Drug information of Maxipime® as supplied by the manufacturer
6. Chetaille E, Hary L, de Cagny B et al. Crises convulsives associées a un surdosage en céfépime. Therapie 1998; 53: 167-168
7. Ferrara N, Abete P, Giordano M et al. Neurotoxicity induced by cefepime in a very old hemodialysis patient. Clin Nephrol 2003; 59: 388-390
8. Jallon P, Fankhauser L, Du Pasquier R et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386
9. Martinez-Rodriguez JE, Barriga FJ, Santamaria J et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001; 111: 115-119
10. Fishbain JT, Monahan TP, Canonico MM. Cerebral manifestations of cefepime toxicity in a dialysis patient. Neurology 2000; 55: 1756-1757
11. Dixit S, Kurle P, Buyan-Dent L et al. Status epilepticus associated with cefepime. Neurology 2000; 54: 2153-2155
12. Chatellier D, Jourdain M, Mangalaboyi J et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002; 28: 214-217
13. Chow KM, Szeto CC, Hui AC et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003; 23: 369-373
14. Wong KM, Chan WK, Chan YH et al. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant 1999; 14: 2265-2266
15. Maganti R, Jolin D, Rishi D et al. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006; 8: 312-314
16. Dakdouki GK, Al-Awar GN. Cefepime induced encephalopathy. Int J Infect Dis 2004; 8: 59-61
17. Neu HC. Safety of cefepime: a new extended spectrum parenteral cephalosporin. Am J Med 1996; 100: 68S-75S
18. Macdonald RL, Barker JL. Specific antagonism of GABA-mediated post-synaptic inhibition in cultured mammalian spinal cord neurons: a common mode of convulsant action. Neurology 1978; 28: 325-330
19. Sugimoto M, Uchida I, Mashimo T et al. Evidence for the involvement of GABAa receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45: 304-314
20. Schmaldienst S, Traunmuller F, Burgmann H et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000; 5: 61-64
21. Huang CK, Chen YS, Lee SS et al. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. J Microbiol Immunol Infect 2002; 35: 159-167
22. Kieft H, Hoepelman AIM, Rozenberg-Arska M et al. Cefepime compared with ceftazidime as initial treatment for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother 1994; 38: 415-421
23. Clermont G, Acker CG, Angus DC et al. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002; 62: 986-996
24. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417-430
25. Le Gall JR, Alberti C, Brun Buisson C. Epidemiology of infection and sepsis in intensive care unit patients. Bull Acad Natl Med 2004; 188: 1115-1125
26. Paul M, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 58: 479-480